Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Adding mepolizumab to standard therapy significantly reduces systemic corticosteroid exposure in COPD patients with an eosinophilic phenotype. A pooled analysis of three phase 3 trials found that patients on mepolizumab spent more days steroid-free and had meaningfully lower total steroid doses compared to placebo — good news for reducing the serious side effects that come with long-term steroid use.
For patients with severe COPD and an eosinophilic phenotype, long-term systemic corticosteroid use is a necessary but risky reality — linked to a host of serious comorbidities. New data presented at the CHEST Annual Meeting suggest that adding the biologic mepolizumab (Nucala, GSK) to standard inhaled triple therapy can meaningfully reduce that steroid burden.
A pooled analysis of 2,089 patients across three phase 3 trials (MATINEE, METREX, and METREO) found that patients on mepolizumab spent more days free of systemic corticosteroids and had lower total steroid exposure over the year compared to those on placebo — a finding that held across two blood eosinophil count (BEC) threshold groups.
Why it matters: Systemic steroids remain a cornerstone of COPD exacerbation management, but their long-term use carries significant risks. These findings support mepolizumab as a steroid-sparing strategy in eosinophilic COPD — and suggest that steroid exposure should be considered a key outcome metric when evaluating new biologics in this population.
